337 related articles for article (PubMed ID: 26604936)
1. Prevention and treatment of bone fragility in cancer patient.
Ottanelli S
Clin Cases Miner Bone Metab; 2015; 12(2):116-29. PubMed ID: 26604936
[TBL] [Abstract][Full Text] [Related]
2. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
3. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
4. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
[TBL] [Abstract][Full Text] [Related]
5. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
[TBL] [Abstract][Full Text] [Related]
6. Skeletal health in breast cancer survivors.
Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
[TBL] [Abstract][Full Text] [Related]
7. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
8. Management of bone loss due to endocrine therapy during cancer treatment.
Khan MI
Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
[TBL] [Abstract][Full Text] [Related]
9. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
10. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
11. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky AM
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
[TBL] [Abstract][Full Text] [Related]
12. Background to and management of treatment-related bone loss in prostate cancer.
Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
[TBL] [Abstract][Full Text] [Related]
13. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of side-effects of systemic treatment: bone loss.
Body JJ
Ann Oncol; 2010 Oct; 21 Suppl 7():vii180-5. PubMed ID: 20943612
[TBL] [Abstract][Full Text] [Related]
15. The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.
Cianferotti L; Bertoldo F; Carini M; Kanis JA; Lapini A; Longo N; Martorana G; Mirone V; Reginster JY; Rizzoli R; Brandi ML
Oncotarget; 2017 Sep; 8(43):75646-75663. PubMed ID: 29088899
[TBL] [Abstract][Full Text] [Related]
16. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
Body JJ; Bergmann P; Boonen S; Boutsen Y; Devogelaer JP; Goemaere S; Reginster JY; Rozenberg S; Kaufman JM
Osteoporos Int; 2007 Nov; 18(11):1439-50. PubMed ID: 17690930
[TBL] [Abstract][Full Text] [Related]
17. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.
Doria C; Leali PT; Solla F; Maestretti G; Balsano M; Scarpa RM
Clin Cases Miner Bone Metab; 2016; 13(3):195-199. PubMed ID: 28228781
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
Ross RW; Small EJ
J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of denosumab in men with prostate cancer.
Sølling AS; Harsløf T; Brockstedt HK; Langdahl B
Osteoporos Int; 2023 Feb; 34(2):291-297. PubMed ID: 36402867
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]